GlassScriptPhysician profile
Alana D Pringle
NPI 1770879686
$5,757.41
in general payments reported to CMS, 2019-2025
45 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $345 · 2021: $801 · 2022: $742 · 2023: $1,134 · 2024: $979 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,358 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,357.76 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,048.76 | 2021-2025 | |
| Novo Nordisk INC | $671.36 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $594.63 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $422.73 | 2019-2025 | |
| Amgen INC. | $396.26 | 2019-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $351.06 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $310.56 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.67 | 2019-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $186.34 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $155.34 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.11 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $97.33 | 2021-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $85.01 | 2019-2021 | |
| Corium, LLC | $81.46 | 2023 | Azstarys, Adlarity |
| Biohaven Pharmaceuticals, INC. | $75.92 | 2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alana Pringle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.